Antwort zum Leserbrief: Ketamininfusionstherapie zur Behandlung von Depressionen – Schritt für Schritt

• Literatur

• 1 Terao I, Tsuge T, Endo K. et al. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis. J Affect Disord 2024; 346: 49-56
• 2 d’Andrea G, Pettorruso M, Di Lorenzo G. et al. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data. J Affect Disord 2024; 348: 314-322
• 3 Gastaldon C, Raschi E, Kane JM. et al. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. Psychother Psychosom 2021; 90: 41-48
• 4 Sanacora G, Frye MA, McDonald W. et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017; 74: 399-405
• 5 Kelson M, Burnett JM, Matthews A. et al. Ketamine Treatment for Alcohol Use Disorder: A Systematic Review. Cureus 2023; 15: e38498
• 6 Goldfine CE, Tom JJ, Im DD. et al. The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Front Psychiatry 2023; 14: 1141836